MT1980 / Monument Therap, TRx Biosci - LARVOL DELTA

MT1980: translating anti-inflammatory and metabolic mechanisms into new treatment opportunities for schizophrenia (CINP 2026) - "MT1980 addresses a key limitation of prior anti-inflammatory approaches in psychiatry by combining effective blood–brain barrier penetration with central anti-inflammatory activity and metabolic benefit. Through PPAR-α–mediated modulation of neuroinflammation and downstream effects on kynurenine pathway activity, MT1980 has the potential to influence signalling relevant to negative symptoms, and possibly positive and cognitive symptom domains. These data support further development of MT1980 for inflammation-associated schizophrenia."

Cardiovascular • CNS Disorders • Inflammation • Metabolic Disorders • Psychiatry • Schizophrenia • IL6

TARGETING NEUROINFLAMMATION IN NEURODEGENERATIVE DISORDERS: A FIRST IN HUMAN STUDY OF MT1980, A NOVEL FORMULATED ANTI-INFLAMMATORY MEDICINE (ADPD 2023) - "Concentrations of drug achieved in the CSF were at levels anticipated to provide meaningful anti-inflammatory effects, suggesting MT1980 has potential utility as a novel treatment of neuroinflammatory conditions. A further clinical study to assess PK and anti-neuroinflammatory effects is now planned."

P1 data • Alzheimer's Disease • CNS Disorders • Immunology • Inflammation

Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Monument Therapeutics Limited | Active, not recruiting ➔ Completed

Trial completion • Inflammation

Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Monument Therapeutics Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Inflammation

Safety & PK of Single Doses of MT1980 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Monument Therapeutics Limited

New P1 trial • Inflammation